Market capitalization | $11.12b |
Enterprise Value | $15.74b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 158.96 |
EV/Sales (TTM) EV/Sales | 3.56 |
P/S ratio (TTM) P/S ratio | 2.52 |
P/B ratio (TTM) P/B ratio | 3.14 |
Revenue growth (TTM) Revenue growth | 4.39% |
Revenue (TTM) Revenue | $4.42b |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
11 Analysts have issued a Catalent Inc forecast:
11 Analysts have issued a Catalent Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 4,422 4,422 |
4%
4%
|
|
Gross Profit | 965 965 |
1%
1%
|
|
EBITDA | 645 645 |
4%
4%
|
EBIT (Operating Income) EBIT | 155 155 |
18%
18%
|
Net Profit | -413 -413 |
58%
58%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies; Biologics and Specialty Drug Delivery; Oral Drug Delivery; and Clinical Supply Services. The Softgel Technologies segment formulate, develop, and manufacture services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufacture services for blow-fill-seal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies, and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules, and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered in Somerset, NJ.
Head office | United States |
CEO | Alessandro Maselli |
Employees | 16,900 |
Founded | 1933 |
Website | www.catalent.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.